BioSpace News Archive

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations supporting the clinical value of its Precision Oncology portfolio will be shared in ten abstracts and three presentations at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).

TransCode Therapeutics, Inc. announced that it withdrew the Registration Statement on Form S-1 it filed with the U.S. Securities and Exchange Commission on November 28, 2022, and amended on November 30, 2022.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA).

ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. (“Lakeshore”) (Nasdaq: LAAA), a publicly traded special purpose acquisition company.

Antengene Corporation Limited recently announced that Amily Zhang has been appointed as the Company’s Chief Medical Officer, succeeding Dr. Kevin Lynch who will continue working with Antengene in a senior advisory role.

Pasithea Therapeutics Corp. today announced that Lawrence Steinman, Pasithea’s Chairman and a member of the National Academy of Sciences, will present preclinical data for PAS-003 in a discussion entitled “Targeting alpha5 Integrin in ALS.”

AbbVie and HotSpot Therapeutics, Inc. today announced an exclusive worldwide collaboration and option to license agreement for HotSpot’s discovery-stage IRF5 program for the treatment of autoimmune diseases.

Dragonfly Therapeutics, Inc. (“Dragonfly”), a biotechnology company developing novel therapies that harness the immune system to treat a broad range of diseases, today announced that the first patients have been dosed in the Phase 2 study of its HER2 targeting TriNKET® DF1001.

Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan.